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Abstract
Objective To review the published literature on the effi-
cacy of ketamine for the treatment of suicidal ideation (SI).
Methods The PubMed and Cochrane databases were
searched up to January 2015 for clinical trials and case
reports describing therapeutic ketamine administration to
patients presenting with SI/suicidality. Searches were also
conducted for relevant background material regarding the
pharmacological function of ketamine.
Results Nine publications (six studies and three case
reports) met the search criteria for assessing SI after
administration of subanesthetic ketamine. There were no
studies examining the effect on suicide attempts or death
by suicide. Each study demonstrated a rapid and clinically
significant reduction in SI, with results similar to previ-
ously described data on ketamine and treatment-resistant
depression. A total of 137 patients with SI have been
reported in the literature as receiving therapeutic ketamine.
Seven studies delivered a dose of 0.5 mg/kg intravenously
over 40 min, while one study administered a 0.2 mg/kg
intravenous bolus and another study administered a liquid
suspension. The earliest significant results were seen after
40 min, and the longest results were observed up to
10 days postinfusion.
Conclusion Consistent with clinical research on ketamine
as a rapid and effective treatment for depression, ketamine
has shown early preliminary evidence of a reduction in
depressive symptoms, as well as reducing SI, with minimal
short-term side effects. Additional studies are needed to
further investigate its mechanism of action, long-term
outcomes, and long-term adverse effects (including abuse)
and benefits. In addition, ketamine could potentially be
used as a prototype for further development of rapid-acting
antisuicidal medication with a practical route of adminis-
tration and the most favorable risk/benefit ratio.
Key Points
Preliminary data from randomized controlled trials
have demonstrated that ketamine may rapidly and
effectively control treatment-resistant depression,
though the effects are transient.
A small subset of studies has demonstrated similar
results in the effects of ketamine on suicidal ideation.
Ketamine has potential as a rapid treatment for
suicidal ideation and/or a possible model compound
for future drug development.
1 Introduction
For decades, ketamine has been recognized as an anes-
thetic by the medical and veterinary worlds. It has long
been used as an anesthetic for children [1] and is also
occasionally used as an anesthetic for administration of
electroconvulsive therapy (ECT) to patients with high
seizure thresholds [2]. Its use for medical indications is
attributable to its safety and wide therapeutic range [3].
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Only recently has it been utilized for the treatment of
depression and suicidal ideation (SI). First described by
Berman et al. [4], ketamine has since been observed in
several small randomized controlled trials to rapidly
reduce depressive symptoms and SI [4–11]. Several
review papers and recommendations have been written
regarding application of ketamine in treatment-resistant
depression (TRD), as well as for depressive episodes of
bipolar disorder, but few have directly addressed its use-
fulness for treating SI. Nonetheless, a recent post hoc
analysis of four studies found that ketamine has an impact
on SI that is independent of improvement in depression
and anxiety [12]. Therefore, the aim of the current review
is to provide an overview of the data describing the
clinical efficacy of ketamine in SI. There are no current
studies that have examined ketamine for suicide attempts
and suicidal behavior as outcomes.
2 Methods
The PubMed and Cochrane databases were searched by the
two authors (L. R. and N. A. Y.) independently to select
relevant studies published up to January 2015, using
combinations of the terms ‘‘ketamine,’’ ‘‘suicidal idea-
tion,’’ ‘‘suicide,’’ ‘‘suicidal,’’ and ‘‘suicidality.’’ After all
publications were obtained, the articles were individually
reviewed and the following inclusion criteria were used for
selection: the publication was in the English language; the
patients had SI measured at baseline; and the publication
was in a peer-reviewed journal. Because only a limited
number of studies directly assessed SI, we included ran-
domized controlled trials, open-label uncontrolled studies,
and case series/reports. A total of 41 articles were
reviewed, and nine met our inclusion criteria (Fig. 1). A
combination of relevant reference citations within the ori-
ginal nine publications and additional searches for neces-
sary background information completed the total data
collection.
3 Results
A total of nine publications (six studies and three case
reports) investigated the efficacy of ketamine for SI [4, 7,
10, 11, 13–17]. Three of these studies were randomized
controlled trials [4, 11, 18], three were open-label non-
randomized studies [15–17], and three were case reports
[10, 13, 14]. Similar to the findings of studies examining
patients with TRD, a reduction in SI was seen as early as
40 min and lasted for an average of 3 days. The results are
summarized in Table 1 and are discussed further below.
In the first study, by Berman et al. [4], depressive
symptoms, as assessed by the Hamilton Depression Rating
Scale (HDRS), were measured before and after ketamine
administration. As a secondary measure, an item-level
analysis of the suicidality item on the HDRS was also
performed. Although the specific scores on the suicidality
item were not reported, the authors reported a statistically
significant reduction (p = 0.02) between the baseline and
final scores of suicidality.
Similarly, in their randomized controlled add-on trial,
Zarate et al. [7] examined SI as a secondary outcome,
using the Montgomery–A˚sberg Depression Scale
(MADRS), HDRS, and Beck Depression Inventory (BDI)
surveys. There were significant reductions in suicidality
item scores in the 15 participants included in the study,
beginning at 40 min and lasting for 3 days on the MADRS
(p \ 0.001 for all three rating scales). The effects lasted for
2 days as assessed by the HDRS, and for up to 10 days as
assessed by the BDI. After the ketamine infusion, there was
a statistically significant improvement in suicidality on the
suicide items of all three rating scales.
An open-label study by Price et al. in 2009 [16] exam-
ined the effects of ketamine on SI, using the MADRS
suicidal ideation item (MADRS-SI) and Implicit Asso-
ciation Test (IAT) measurements. Twenty-six patients with
TRD were recruited. A subset of 13 of them had significant
baseline SI (MADRS-SI score C4). These patients were
administered ketamine 0.5 mg/kg intravenously over
40 min. Among the 13 patients, 8 (62 %) had an MADRS-
SI score of B1 24 h postinfusion, 3 (23 %) had a score of
2–3, and two (15 %) remained at or above an MADRS-SI
score of 4. The overall average reduction in MADRS-SI
scores was just over 2 (p \ 0.001). It is interesting to
report the results unique to that study related to implicit
measures of suicidality. In a separate subset of 12 patients,
implicit measures were assessed using the IAT, which
assesses implicit suicidal associations and is a ‘‘behavioral
Fig. 1 Search strategy for the systematic review of ketamine as a
treatment for suicidal ideation or suicidality
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measure of suicidal cognition.’’ Statistical analysis re-
vealed that stronger implicit associations correlated with
higher MADRS-SI scores, and the implicit measurements
significantly decreased after the ketamine infusion
(p = 0.003).
In another open-label study, 33 patients with TRD cur-
rently experiencing a major depressive episode were given
ketamine 0.5 mg/kg intravenously for specific observation
of its effects on SI. SI was measured on four surveys: the
Scale for Suicide Ideation (SSI), MADRS, HDRS, and
BDI. The authors specifically used the SSI to determine the
presence of baseline suicidality, and they found that 10 of
the 33 patients had significant SSI scores of [4. In this
population, significant decreases in symptoms (SSI scores
of \4) were seen beginning at 40 min in nine of the
patients and at 80 min in the tenth one. The average time to
an SSI score of 0 for all 10 patients was 2 h. The
improvement in their clinical symptoms lasted for up to
4 h. When the 33 patients were analyzed together, clinical
improvement was seen across all four suicide scales from
40 to 230 min (p \ 0.001) [17].
Larkin and Beautrais [15] followed 14 patients who
presented with SI to the emergency department (ED). The
patients received an intravenous bolus of ketamine
0.2 mg/kg over 1–2 min. After the infusion, they were
followed for 10 days and their symptoms were measured
using the MADRS. These patients saw significant
improvements in their clinical symptoms, beginning at
40 min, with the MADRS-SI score decreasing from 3.9 to
0.6. The patients subjectively reported relief of SI, which
lasted for the 10 days that they were followed.
In their case report, Zigman and Blier [14] described how
a single infusion of ketamine 0.5 mg/kg over 40 min sta-
bilized a patient with TRD and suicide intent with a plan.
The patient had made a previous suicide attempt but had no
other psychiatric history. She presented with an MADRS
score of 48 and SI. She elected to receive ketamine rather
than ECT. The patient reported immediate relief of her
symptoms after the 40-min infusion. The patient reported
that the effect of ketamine lasted for 8 days, and she denied
any return of SI for the following month.
The second and third case reports, published by Harihar
et al. [13], followed two patients with depression and sui-
cidality. The first patient had a psychiatric history of
obsessive–compulsive disorder and worsening depression,
including suicidal thoughts. He received ketamine
0.5 mg/kg intramuscularly after admission to the hospital
for a suicide attempt. His HDRS score changed from a
baseline of 17 to 4, 2 h after the ketamine treatment. The
second patient had a history of recurrent major depression
with recently worsening SI. After the same dose of keta-
mine, his HDRS score changed from 21 to 6. Neither pa-
tient reported any side effects.
The most recent case reports documented two patients
with TRD, chronic SI, and multiple past suicide attempts.
Both patients were given ketamine 0.5 mg/kg in a liquid
suspension. For the first patient, his dose was titrated up to
3 mg/kg, where he attained a maximum response without
side effects. His baseline MADRS-SI score was 4/6, and
24 h after the ketamine treatment, it had decreased to 1/6.
The authors reported sustained remission with repeated
oral dosing. However, no follow-up assessment was done.
Similar results were seen in the second patient. The patient
received a maximum dose of oral ketamine solution
1.5 mg/kg. She achieved a change in her MADRS-SI score
from 4/6 to 2/6 after 24 h, and the authors also reported
that she had sustained clinical remission of SI with monthly
oral doses of ketamine [10].
The largest study to date included 57 patients with TRD
in a randomized double-blind placebo-controlled trial [11].
Patients were randomized to receive either ketamine
0.5 mg/kg intravenously over 40 min or midazolam
0.045 mg/kg intravenously. Patients who were thought to
be at imminent suicide risk were excluded from the study
because of ethical considerations about using a placebo. A
total of 36 patients received ketamine, and 21 received
midazolam. As in the previous study conducted by this
group, the patients were assessed for explicit and implicit
suicidality. A combination of the Beck Scale for Suicide
Ideation (BSS), MADRS-SI, and the Quick Inventory of
Depressive Symptomatology-Self Report (QIDS-SR)
comprised the explicit measurements in a measurement
termed ‘‘SI composite scores,’’ while the IAT looked at
implicit associations. Results were compared 24 h after
treatment. The ketamine treatment group experienced a
greater reduction in SI composite scores than the placebo
group (p = 0.01). In addition, 53 % of the treatment group
scored 0 on explicit measures of suicide after 24 h, while
only 24 % of the placebo group scored 0 (p = 0.03). When
looking at implicit measures, the authors found no differ-
ence in the effect on implicit suicidality, based on the
treatment after 24 h. They did note that the scores for one
item on the IAT, ‘‘escape = me,’’ decreased from baseline
only in the ketamine group [11].
4 Discussion
With an estimated prevalence of mood disorders ranging
from 3.3 to 21.4 % and the substantially increased risk of
suicide among patients with mood disorders, treatment is
certainly warranted [19]. Current treatment options for
suicidality are limited. They include brain stimulation
therapeutics, such as ECT, and pharmacological interven-
tion (lithium, clozapine). The efficacy of lithium in treating
suicidality has been documented [20, 21] and has recently
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been reviewed and pooled in a recent meta-analysis of 48
studies [22]. Clozapine has also been shown to reduce
suicide risk in patients with schizophrenia [23, 24]. The
limitations of both lithium and clozapine include a longer
time to efficacy in this psychiatric emergency/urgency,
compared with the early response to ketamine [25]. Keta-
mine seems to be gaining substantial evidence as a phar-
macological option for depression with a fast onset of
action, but its long-term effects need further investigation.
In addition, ketamine probably offers a faster onset of
action in terms of SI, but further work is certainly needed
in this area. Given the risk of suicide and even the
increasing rates of suicide in certain subgroups, such as
soldiers and veterans [26, 27], there is an urgent need for
faster therapeutics for SI and TRD. Importantly, suicidality
and suicide pose a high global burden of patient suffering
to families and society. Although several small-to-moder-
ate sized studies, in addition to several reviews, have been
published that have examined the efficacy of ketamine in
TRD, there are considerably fewer published data
specifically examining ketamine in patients presenting with
SI. Notably, only three studies have directly examined SI
as the primary outcome [11, 16, 17], while the rest
examined SI as the secondary outcome [4, 15, 18], not
including case reports. This review summarizes the current
published literature regarding ketamine as a treatment for
SI. The data so far show promising trends of ketamine
being an effective and rapid treatment with minimal side
effects.
Pharmacologically, ketamine is an N-methyl-D-aspartate
(NMDA) receptor antagonist. It has been used for anes-
thesia in the USA since the 1970s. At subanesthetic doses,
ketamine has been shown to increase glutamate levels [3].
This mechanism is relevant, as glutamate regulation and
expression are altered in patients with major depressive
disorder (MDD). Studies have also demonstrated an
abnormal glutamate–glutamine–gamma-aminobutyric acid
cycle in patients with suicidality [28]. Furthermore, keta-
mine has also been shown to work on nicotinic and opioid
receptors [29]. No other class of antidepressant medication
works to modulate the glutamatergic system, and research
continues into this, with the goal of characterizing the full
mechanism of action of ketamine and perhaps developing
other compounds that would have similar effects. Thus,
even if the approval and marketing of ketamine as a rapid-
acting antisuicidal and antidepressant medication is not
realized, it could well be a prototype for development of
other medication(s) that retain the mechanism of action
with more favorable qualities and a lesser adverse effect
profile (such as a longer duration of action or less or no
addictive potential). Although the mechanisms explaining
the antisuicidal effect and the NMDA receptor antagonism
of ketamine are still unclear, some of the initial evidence
points to an anti-inflammatory action via the kynurenic
acid pathway. Strong suggestions as to the causal rela-
tionship between inflammation and depression/suicidality
has come from studies demonstrating that cytokines [30,
31] and interferon-b [32] induce depression and suicidality.
Other recent studies have added to the notion of implicat-
ing brain immune activation in the pathogenesis of suici-
dality. For instance, one study showed microglial
activation of postmortem brain tissue in suicide victims
[33]. Another study found increased levels of the cytokine
interleukin-6 in cerebrospinal fluid from patients who had
attempted suicide [34]. Higher levels of inflammatory
markers have been shown in suicidal patients than in non-
suicidal depressed patients [33, 35]. Inflammation leads to
production of both quinolinic acid (an NMDA agonist) and
kynurenic acid (a NMDA antagonist). An increased
quinolinic acid to kynurenic acid ratio leads to NMDA
receptor stimulation. The correlation between quinolinic
acid and Suicide Intent Scale scores indicates that changes
in glutamatergic neurotransmission could be specifically
linked to suicidality [36].
Small randomized controlled trials have demonstrated
the efficacy of ketamine in rapidly treating patients with
both TRD and/or bipolar depression [4, 8, 9, 11, 16–18].
Some studies have also examined suicide items as a sec-
ondary measure in their depression rating scales [4, 7]. In
total, the studies examining ketamine and TRD have nearly
consistently demonstrated that ketamine provides relief
from depressive and suicidal symptoms, starting at 40 min
and lasting for as long as 5 days. Questions still remain as
to the long-term effects of this treatment, how much should
be administered and how often, any serious adverse effects,
and the mechanism of action.
Pharmacologically, ketamine has poor bioavailability
and is best administered via injection [37]. In their land-
mark study, Berman et al. [4] found that a subanesthetic
dose (0.5 mg/kg) rapidly improved depressive symptoms.
Most of the subsequent studies have delivered ketamine as
a constant infusion for 40 min at a rate of 0.5 mg/kg.
Others have examined its efficacy after multiple infusions
and observed similar results [8, 13, 16, 38]. Currently, it is
recommended that ketamine be administered in a hospital
setting [39].
Ketamine is considered to be a safe compound; how-
ever, it is not without its side effects. Some studies have
reported symptoms of dissociation and hallucinations,
although these are usually transient [7, 14, 18]. A recent
study of ketamine administration in 10 patients with
obsessive–compulsive disorder reported an increase in
anxiety and suicidal thoughts in two patients [40]. Notably,
these patients had extensive psychiatric comorbidity, and
these findings have not been duplicated. Another potential
concern is the long-term effects of ketamine. Studies
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regarding outcomes associated with long-term ketamine
use are sparse. The current literature refers to patients who
have abused ketamine as a recreational drug. In this
population, the long-term consequences have not been
described, but it is clear that further studies are needed in
this area [3].
The weaknesses of this review include possible bias in
the way in which studies were selected for inclusion—
including publication and selection bias. The literature is
limited on this topic, as we have noted in this review.
However, this review includes recent data from several
randomized controlled trials, including one recent double-
blind placebo-controlled trial. These trials were conducted
by different groups and demonstrated similar findings. It
must also be noted that differences in patient populations
were not explored among the papers cited in this review.
Some aspects of the efficacy of ketamine may be dependent
on patient age, race, gender, etc., as evidenced by the
differences in effect sizes noted among the studies, even
when they used the same dosages and the same measure-
ment tools. Larger studies with greater numbers of patients
are needed to assess this further.
There are still several questions that need to be answered
if standard clinical use of ketamine as an agent for treatment
of SI is to be definitively pursued. Further studies are needed
to better identify the best dose and delivery method of
ketamine. Studies should specifically be conducted to assess
SI as the primary, not secondary, outcome. Studies are also
needed to further characterize the long-term benefits (if any)
and the long-term risks/adverse effects, especially the abuse
potential [41]. Also, there are no data on prevention of sui-
cide attempts or death by suicide. More information is also
warranted to gain a better understanding of the mechanism of
action of ketamine. This information could provide guidance
for further drug development, as well as further insight into
the pathogenesis of suicidality. Additionally, the exploration
of compounds that function similarly to ketamine warrants
attention. One of these compounds may be scopolamine, an
antagonist at cholinergic muscarinic receptor sites. Studies
have demonstrated effective resolution of depressive
symptoms within 3 days of treatment with scopolamine in
some patients [42]. Also, the metabolite norketamine, which
may be a possible player in the antidepressant and/or
antisuicidal effect of ketamine [43, 44], deserves further
research. Investigations into ketamine and other promising
agents for emergent treatment of suicidality merit further
research and replication in larger studies, in addition to fur-
ther understanding of the mechanism of action. It should be
noted that although NMDA antagonism has been proposed as
the primary mechanism of action, some researchers have
questioned that and raised the possibility that its stimulant
action or opiate agonism might be more important than is
currently appreciated [41].
5 Conclusion
There is early preliminary evidence not only for the an-
tidepressant action but also for the rapid antisuicidal action
of ketamine. Further research is needed to achieve better
understanding of the mechanism of action and the most
appropriate route of administration, to better define dosing,
and to examine the long-term adverse effects (including
abuse potential) and benefits of ketamine, while exploring
potential similar medications that might provide better side
effect profiles, or that are more easily administered, in
larger double-blind randomized clinical trials.
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